Outlook Therapeutics Sees Unusually Large Options Volume (NASDAQ:OTLK)

Outlook Therapeutics, Inc. (NASDAQ:OTLK) was the recipient of some unusual options trading on Friday. Investors acquired 10,260 call options on the stock. This is an increase of approximately 6,976% compared to the typical daily volume of 145 call options.

Insider Buying and Selling at Outlook Therapeutics

In related news, CFO Lawrence A. Kenyon bought 5,000 shares of the stock in a transaction on Thursday, September 26th. The shares were purchased at an average price of $5.69 per share, with a total value of $28,450.00. Following the purchase, the chief financial officer now owns 5,946 shares in the company, valued at approximately $33,832.74. This represents a 528.54 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.40% of the stock is owned by company insiders.

Institutional Trading of Outlook Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Rosalind Advisors Inc. increased its position in shares of Outlook Therapeutics by 44.3% in the second quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock worth $3,321,000 after acquiring an additional 138,225 shares in the last quarter. LVW Advisors LLC acquired a new position in Outlook Therapeutics in the 2nd quarter worth approximately $352,000. Great Point Partners LLC grew its position in Outlook Therapeutics by 15.0% during the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after purchasing an additional 221,510 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Outlook Therapeutics during the 2nd quarter valued at $232,000. Finally, AQR Capital Management LLC purchased a new stake in shares of Outlook Therapeutics in the second quarter valued at $75,000. Institutional investors and hedge funds own 11.20% of the company’s stock.

Outlook Therapeutics Stock Up 20.6 %

Shares of Outlook Therapeutics stock opened at $2.05 on Friday. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85. The firm has a market capitalization of $48.50 million, a PE ratio of -0.19 and a beta of 0.62. The stock’s fifty day moving average is $5.29 and its 200-day moving average is $6.71.

Analyst Ratings Changes

A number of research firms recently commented on OTLK. Chardan Capital reiterated a “buy” rating and set a $53.00 price objective on shares of Outlook Therapeutics in a research note on Friday, August 16th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a research note on Friday. Ascendiant Capital Markets decreased their target price on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Finally, BTIG Research lowered their target price on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Outlook Therapeutics currently has an average rating of “Buy” and an average target price of $42.34.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.